FDA Approval Bleeds Omrix's Stock
519593
Was the approval already built into the stock price?
564679
Documents released ahead of an FDA meeting foretell a tougher future for Amgen's top drugs.
512456
NEW YORK, September 9 (New Ratings) - The FDA has raised questions regarding AstraZenecaâs (AZN.NYS) blood thinner, Exanta. The leading pharmaceutical companyâs hopes had been pinned on Exanta, which
144602
Shares of Radiation Therapy (RTSX:Nasdaq - news - research) were among the worst-performing health and pharmaceutical stocks Thursday after Banc of America Securities initiated coverage with a sell rating.
551163
Stocks to watch on Wednesday: FOREST LABORATORIES INC. (FRX.N: Quote, Profile, Research). The drug company&#39;s experimental treatment for Alzheimer&#39;s failed to prove effective in a big clinical trial.
405424
Shares of OSI Pharmaceuticals Inc. fell sharply Friday on concerns about the newly approved drug&#39;s ability to meet sales targets.
131381
Uncertainty is spreading like a cancer in the pharmaceutical investing world, and that&#39;s bad news for the segment&#39;s kingpin, Pfizer (NYSE: PFE).
521996
It'll be awhile before the FDA makes its decision and the stock price settles down.
691976
Washington, Dec 16 : One-fifth of the US Food and Drug Administration (FDA) scientists surveyed as part of an official review have said they had been pressured to recommend approval of a new drug despite their reservations about its safety, effectiveness
311418
Investors in pharmaceuticals were dealt  a triple whammy on Friday as Pfizer Inc, AstraZeneca Plc and  Eli Lilly and Co all shocked the market with bad news about key  products.
607304
Food and Drug Administration approvals kept medical device and drug company stocks in the spotlight with two device companies reporting product approvals Wednesday.
335721
Shares of large U.S. and European drug  makers fell on Thursday after a prominent cardiologist  questioned the safety of new arthritis drugs and the  performance of U.S. regulators in monitoring drug safety.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the
632359
Shares of Atherogenics Inc. opened down 7.2 percent on the Nasdaq Wednesday following a pre-market report that the drug developer is abandoning further clinical trials of its AGIX-4207 treatment for rheumatoid arthritis.
646800
Gaithersburg-based GenVec has run into a problem with its top drug candidate, and investors have had an adverse reaction. GenVec says the US Food and Drug Administration has requested that clinical trials
108463
Pfizer is a good company, but a bad stock for 2008.
167015
PARIS/LONDON  - Sanofi-Aventis shares rose on   Friday after a U.S. judge blocked further sales of generic   Plavix, but gains were capped as it warned cheap supplies of   the blood-thinner already in the market would hit 2006 profits.